The differences in dfs and os between those three subgroups were significant (all p < 0.05 in paired comparisons). Multivariate Cox regression showed that subtype and ypN staging adjusted by pcr were the only two independent factors predicting dfs.
INTRODUCTION
In breast cancer management, surgical nodal staging reflects initial axillary status in patients having surgery as initial treatment, and it is always an important prognostic factor 1, 2 . However, in neoadjuvant settings, nodal metastasis can readily be eradicated by preoperative treatment, which changes the initial axillary status substantially [3] [4] [5] . Therefore, whether axillary restaging is still able to predict prognosis after neoadjuvant chemotherapy (nac) is of interest. On the other hand, because of receptor status-based subtype stratification and subtype-oriented therapeutic strategies, breast cancer is no longer viewed as a single disease [6] [7] [8] . Evaluations of any prognostic factor should therefore take subtypes and treatments into account.
Moreover, pathologic complete response (pcr) after nac has been established as an independent prognostic factor, at least in the human epidermal growth factor receptor 2-positive (her2+) and triplenegative breast cancer (tnbc) subtypes [9] [10] [11] . Nonetheless, the reported pcr rate of 16% overall from an update analysis of the National Surgical Adjuvant Breast and Bowel Project B18 and B27 trials suggests
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Background
Our retrospective study in breast cancer patients evaluated whether integrating subtype and pathologic complete response (pcr) information into axillary lymph node restaging after neoadjuvant chemotherapy (nac) adds significance to its prognostic values.
Methods
Patients included in the analysis had stage ii or iii disease, with post-nac axillary lymph node dissection (alnd), without sentinel lymph node biopsy before completion of nac, with definitive subtyping data and subtype-oriented adjuvant treatments. The ypN grading system was used to restage axillary lymph node status, and ypN0 was adjusted by pcr in both breast and axilla into ypN0(pcr) and ypN0(non-pcr). Univariate and multivariate survival analyses were performed.
Results
Among the 301 patients analyzed, 145 had tumours that were hormone receptor-positive (hr+) and negative for the human epidermal growth factor receptor (her2-), 101 had tumours that were positive for her2 (her2+), and 55 had tumours that were triple-negative. The rate of pcr in both breast and axilla was 11.7%, 43.6%, and 25.5% respectively for the 3 subtypes. Compared with the non-pcr patients, the pcr patients had better disease-free survival (dfs) and overall survival (os): p = 0.002 for dfs and p = 0.011 for os. In non-pcr patients, dfs and os were similar in the ypN0(non-pcr) and ypN1 subgroups, and in the ypN2 and ypN3 subgroups. We therefore grouped the ypN grading results into ypN0(pcr) (n = 75), ypN0-1(non-pcr) (n = 175), and ypN2-3 (n = 51). In those groups, the 3-year dfs was 98%, 91%, and 56%, and the 3-year os was 100%, 91%, and 82% respectively. that most patients will eventually miss pcr 12 . For this large group of non-pcr patients, the search for surrogates to further stratify subgroups with different long-term outcomes is clinically significant in adjuvant decision-making.
Currently, the ypN classification, an axillary restaging after nac, is used in the American Joint Committee on Cancer staging system for breast malignancies 13 . However, considering the critical roles of pcr and subtype, it is reasonable to assume that integrating the ypN system with pcr and subtype might possibly improve the power of the system to predict prognosis.
To test that hypothesis, we retrospectively analyzed a cohort of Chinese breast cancer patients who received nac and standard subtype-oriented local or systemic adjuvant treatments. We evaluated the feasibility and clinical significance of axillary restaging refined with pcr and subtype.
METHODS
Patients
We reviewed medical records at our institution from June 2006 to June 2011. Inclusion criteria were stage ii or iii non-inflammatory breast cancer in patients who had been treated with at least 1 cycle of nac, who received complete axillary lymph node dissection (alnd), for whom complete estrogen receptor (er), progesterone receptor (pr), and her2 status were available, and who had received subtype-oriented and standard local or systemic adjuvant treatments.
To ensure that the study population had undergone all standard treatments currently available and to minimize possible confounding factors, we set up exclusion criteria. To be specific, her2+ patients who had not received adjuvant trastuzumab treatment were excluded regardless of whether neoadjuvant trastuzumab had been used. Patients who were er positive (er+) and who had not received adjuvant endocrine therapy were also excluded. Patients who had not received radiotherapy per clinical guidelines were not eligible. Patients undergoing sentinel lymph node biopsy (slnb) before neoadjuvant treatment were excluded because the slnb would affect the results of axillary restaging after nac.
Clinicopathologic characteristics, evaluations of clinical and pathologic response, and follow-up data were retrieved for analysis.
Subtype Classification
At our institution, er status, pr status, her2 status, and Ki67 labelling index are routinely examined using standard immunohistochemical methods as reported elsewhere 14 . Positivity for er or pr was defined using a cut-off of 10% or more tumour cells stained in the nucleus. Positivity for her2 was defined as an immunohistochemical 3+ or a positive gene amplification result with fluorescence in situ hybridization. The Ki67 index was reported as the percentage of positive tumour nuclei. Patients were then classified into a hormone receptor-positive [hr+ (er or pr positive, or both)] subtype, a her2-negative (her2-) subtype, a her2+ subtype (her2+ regardless of hr status), and a tnbc subtype (negative for er, pr, and her2).
Although the Ki67 index was adopted to refine breast cancer subtyping in the 2011 St. Gallen Consensus 8 , we did not use it to further stratify our hr+ her2-patients because of the lack of a standardized examination method. However, we included it in the multivariate Cox regression analysis to test its association with prognosis.
Neoadjuvant Regimens and Response
No specific neoadjuvant regimens or number of cycles were required in our study. Regimens were classified as anthracycline-based, taxane-based, anthracycline with taxane, platinum with taxane, and trastuzumab with taxane.
Clinical response was evaluated according to already-established criteria described elsewhere. By comparing the pre-surgery imaging results with the baseline imaging results from both breast and axilla, patients were graded as having complete response, partial response, stable disease, or progressive disease 10 . The pathologic response was evaluated on the final specimens from breast-conserving surgery or mastectomy with alnd. A pcr was defined as no evidence of residual invasive cancer cells in both breast and axilla 15 .
Axillary Restaging After NAC
Patients were classified using the American Joint Committee on Cancer staging system into ypN0 (zero positive nodes), ypN1 (1-3 positive nodes), ypN2 (4-9 positive nodes) and ypN3 (≥10 positive nodes) 13 . Patients classified ypN0 were further classified into ypN0(pcr) and ypN0(non-pcr) depending on whether pcr was achieved in both breast and axilla.
Statistics
Disease-free survival (dfs) was defined as the time interval between the date of definitive surgery and the date of a first recurrence event (locoregional or distant) or the date of last follow-up if no recurrence event was recorded. Overall survival (os) was defined as the time interval between the date of definitive surgery and the date of death or last follow-up.
Kaplan-Meier survival analysis was performed to determine dfs and os. Log-rank tests were used to compare differences between subgroups. Multivariate Cox regression was performed to test the independency of various factors.
All analyses were performed using the SPSS software application (version 19.0: SPSS, Chicago, IL, U.S.A.), and significance was set at p = 0.05.
Substituting ypN with Lymph Node Ratio
Considering that lymph node ratio (lnr) staging has also been suggested as an alternative axillary grading system for breast cancer as reported by others 16 , we used the suggested criteria to categorize lnr in our patients. To be specific, lnr was first calculated as the number of positive nodes divided by the number of harvested nodes. Then, based on the lnr range, patients were classified as LNR0 (lnr = 0), LNR1 (0 < lnr ≤ 0.2), LNR2 (0.2 < lnr ≤ 0.65), and LNR3 (0.65 < lnr ≤ 1.0). Similarly, we further used pcr to stratify patients who were LNR0 into LNR0(pcr) and LNR0(non-pcr). All analyses performed for the ypN grading were also performed for the lnr grading (see Appendix A).
RESULTS
Patient Characteristics
In total, 301 patients were eligible for inclusion in the present study (Table i) . Median age was 46 years, with 267 patients (88.7%) being older than 35 years and 34 (11.3%) being younger than 35 years. In 284 patients (94.4%), the diagnosis was invasive ductal carcinoma; only 17 patients (5.6%) had other histologic types. The disease was classified as grade 3 in 58 patients (19.3%) and grade 1 or 2 in 243 (80.7%). In 233 patients (77.4%), the disease was classified as stage ii, and in 68 (22.6%), as stage iii. In this cohort, 48 patients (15.9%) underwent breast-conserving surgery and 253 (84.1%), mastectomy. All patients underwent complete alnd without pre-chemotherapy slnb. Written informed consent was provided by all patients before treatment.
Subtype Distribution
The cohort included 145 hr+ her2-patients (48.2%), 101 her2+ patients (33.6%), and 55 tnbc patients (18.3%). The hr+ her2-patients were not further stratified into luminal A or luminal B subtypes by Ki67 index, and her2+ patients were not further stratified into the her2+ or luminal B subtype (her2+) according to hr status.
NAC Regimens and Cycles
Among the 301 patients, 92.7% received taxane-containing regimens; only 7.3% received anthracyclinebased regimens. In her2+ patients, most received trastuzumab-containing regimens (96 of 101, 95.0%). The nac cycles ranged from 2 to 10, with a mean cycle number of 4.1.
Response Evaluation
The overall response rate (clinical complete and partial responses) was 80.0% in hr+ her2-patients, 92.1% in her2+ patients, and 80.0% in tnbc patients. The pcr rate was just 11.7% (17 of 145) in hr+ her2-patients, 25.5% (14 of 55) in tnbc patients, and as high as 43.6% (44 of 101) in her2+ patients. The pcr rate was significantly lower in hr+ her2-patients compared with either her2+ (χ 2 = 32.36, p < 0.001) or tnbc patients (χ 2 = 5.74, p = 0.017).
Kaplan-Meier Survival
Median follow-up was 36.2 months. In total, 33 dfs events and 16 deaths were recorded. Table ii shows the distribution of events in the subgroups. In the overall cohort, Kaplan-Meier survival analysis showed that, compared with non-pcr patients, pcr patients experienced better dfs and os [p = 0.002 and 0.011 respectively, Figure 1(A,B) ].
We further used pcr to adjust ypN classifications. Patients were stratified into ypN0(pcr), ypN0(non-pcr), ypN1, ypN2, and ypN3. Pairwise comparisons of dfs and os showed that ypN0(pcr) patients had the best prognosis and that patients classified as ypN0(non-pcr) and ypN1 had overlapping survival curves. Similarly, patients classified as ypN2 and ypN3 also had overlapping survival curves. Figure 2(A,B) shows the Kaplan-Meier survival curves.
Based on those results, we then combined the subgroups with overlapping survival curves. Patients classified as ypN0(non-pcr) and ypN1 were merged as ypN0-1(non-pcr), and those classified as ypN2 and ypN3 were merged as ypN2-3. KaplanMeier survival analysis of all patients stratified by ypN0(pcr), ypN0-1(non-pcr), and ypN2-3 showed that dfs and os were significantly different between these 3 classifications [ Figure 3(A,B) ]. The expected 3-year dfs was 98%, 91%, and 56% respectively. The expected 3-year os was 100%, 91%, and 82% respectively.
Subtype-based analyses using ypN0(pcr), ypN0-1(non-pcr), and ypN2-3 were then performed to compare dfs and os. As Figure 4 shows, this axillary restaging classification effectively discriminated the various dfs results in the 3 subtypes (all p < 0.001). On the other hand, in os analysis, these classifications did not shown statistical significance for the hr+ her2-subtype or the tnbc subtype, probably because only 16 os events occurred, because the hr+ her2-subgroup contained fewer pcr patients, and because the tnbc subtype contained relatively fewer patients overall. However, a notable trend remained in the hr+ her2-and tnbc subgroups, with patients classified as ypN2-3 having the poorest os [ Figure 4(D,F) ]. 
Multivariate Cox Regression Analysis
In multivariate Cox regression analysis, ypN was adjusted for pcr, age, initial clinical stage, initial Ki67 index; intrinsic subtype and initial tumour grade were included as calibrators. Status as ypN1 was used as the reference for other ypN statuses. Similarly, the hr+ her2-subtype was used as the reference for other subtypes. In dfs analysis, ypN adjusted by pcr and intrinsic subtype were two independent predicting factors (p < 0.001 and 0.002 respectively). However, in os analysis, ypN classification was nonsignificant (p = 0.100), and intrinsic subtype had only borderline significance (p = 0.052).
Results by LNR
We performed the same set of analyses substituting lnr for ypN. The results were comparable to those using ypN (see Appendix A).
DISCUSSION
Compared with pre-chemotherapy staging by imaging evaluation and physical examination, post-chemotherapy pathologic restaging is superior in some respects. First, it is based on pathology results, which are definitive and accurate. Second, it measures tumour and axillary response, and thus reflects the efficacy of neoadjuvant treatments 17 . In this sense, axillary pathologic restaging is more objective and potentially feasible for clinical practice.
In recent years, some reports have shown that axillary restaging after nac is a significant prognostic factor 18, 19 . Nonetheless, those studies did not integrate subtype or adjust the restaging system with pcr, which could be problematic considering the increasing evidence showing better prognosis in pcr than in non-pcr patients [10] [11] [12] 15, 20 . The probable result of simply putting those patients into the single ypN0 group is an underestimation of survival in pcr patients and an overestimation in non-pcr patients, thus impairing the accuracy of the axillary restaging system.
The present study adds to the importance and accuracy of the axillary restaging system by integrating pcr information. First, our analysis shows that, compared with ypN0(non-pcr) patients, ypN0 patients achieving pcr experienced significantly better os. Second, differences in dfs between those two subgroups almost approached significance, with a borderline p = 0.078, suggesting a trend in favor of pcr. Those results are consistent with a recent report that has established the role of pcr as a significant prognostic factor 21 . In sum, we strongly recommend that pcr should be used for adjusting ypN0 for the best accuracy when considering axillary restaging.
There are also reports that lnr is a potential prognosis surrogate 16, 22 . However, the original lnr classification was created in the non-neoadjuvant setting, with the rationale that nodal staging would be inaccurate in cases with fewer than 10 harvested axillary lymph nodes. Considering the substantially modified axillary status after nac-and the mean of Hormone receptor-positive (estrogen or progesterone or both), and negative for the human epidermal growth factor receptor 2. c Positive for the human epidermal growth factor receptor 2 (any hormone receptor status). d Negative for the human epidermal growth factor receptor 2 and for both hormone receptors. Pts = patients; hr = hazard ratio; cl = confidence limits; ypN0 = no positive nodes among all axillary nodes harvested; ypN1 = 1-3 positive nodes among all axillary nodes harvested; ypN2 = 4-9 positive nodes among all axillary nodes harvested; ypN3 = ≥10 positive nodes among all axillary nodes harvested; hr = hormone receptor; her2 = human epidermal growth factor receptor 2; tnbc = triple-negative breast cancer.
figure 1 Pathologic complete response (pcr) predicts better survival. Compared with patients not having a pcr, those with a pcr had (A) significantly better disease-free survival (dfs) and (B) significantly better overall survival (os).
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18.6 harvested axillary lymph nodes, with only 3% of patients (9 of 301) having fewer than 10 harvested nodes (Table i) -ypN staging and lnr classification should be comparable, as was expected and observed in the present study (see Appendix A). In addition, our results also support the conclusion drawn by another study that nac does not affect the number of harvested axillary lymph nodes 23 . The ypN classification should therefore be preferred over lnr given that it is already a universally accepted grading system. Subtype stratification was also performed in the present study with the purpose of refining the findings. Rates of pcr were noted to be significantly different between the subtypes. The pcr rate was particularly low in the hr+ her2-patients than in the her2+ or tnbc patients. But the hr+ her2-patients had the best prognosis regardless of response to nac, after that subtype was adjusted for other clinicopathologic variables (Table ii) . In addition, patients with the hr+ her2-subtype achieving pcr did not experience better survival than ypN0(non-pcr) and ypN1 patients [ Figure 4(A,D) ]. On the contrary, our results showed that pcr, ypN0-1(non-pcr), and ypN2-3 patients of the her2+ subtype all had significantly different prognoses [ Figure 4(B,E) ].
These results suggest that that axillary restaging adjusted with pcr may have the power to predict prognosis for the disease subtypes. But, given the 
figure 3 Survival analysis for all patients, stratified by pathologic complete response (pcr). (A) Disease-free survival (dfs) was better for ypN0(pcr) patients than for ypN0-1(non-pcr) and ypN2-3 patients, and for ypN0-1(non-pcr) patients than for ypN2-3 patients. (B) Overall survival (os) was better for ypN0(pcr) patients than for ypN0-1(non-pcr) and ypN2-3 patients, and for ypN0-1(non-pcr) patients than for ypN2-3 patients.
significantly lower pcr rate in hr+ her2-patients, pcr may not be as important in that particular subtype as in the others. Still, these results should not undermine the significance of axillary restaging, because ypN2-3 patients still had the poorest prognosis [ Figures 4(A,D) ] across all subtypes in our study. Moreover, in the present study, patients classified ypN2-3 had the worst long-term outcomes regardless of disease subtype despite all patients in that subpopulation having undergone standard systemic and local adjuvant treatment after nac and curative surgery. That finding raises a question of general interest: Might more-aggressive adjuvant treatment in ypN2-3 patients improve the poor outcomes? In other words, might it be helpful to extend adjuvant trastuzumab to a 2-year duration or to add lapatinib, thus dually targeting her2 in the her2+ subtype? Or to apply ovarian ablation in premenopausal hr+ her2-patients? Or to use an adjuvant chemotherapy regimen different from that used in the neoadjuvant setting for the tnbc subtype?
Such questions are beyond the scope of the present study, but they deserve to be resolved in future well-designed prospective clinical trials, because a prognostic factor will gain much more clinical significance when it can direct therapeutic decision-making and eventually lead to outcome improvements.
Several limitations of our study should be addressed. First, because of the patient selection criteria, our results are applicable only to patients not undergoing slnb before completion of nac. Whether our findings are applicable in the post-slnb setting has to be determined in further studies. Second, the retrospective nature of the study means that the conclusions drawn should be treated with caution because of the possibility of hidden bias. Third, the relatively short follow-up period means that the subtype analysis cannot be considered definitive, especially for the tnbc subtype. Further follow-up is therefore warranted.
CONCLUSIONS
We demonstrated that, in patients without slnb before completion of nac, axillary restaging adjusted by pcr after completion of neoadjuvant treatment is an independent prognostic factor for breast cancer patients. The combination of ypN and pcr status has the power to predict differences in survival between intrinsic disease subtypes. The combined classification is convenient and provides valuable prognostic information. This work deserves further validation for its potential application in future clinical trials.
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